Our Story
Innovation in Targeted Cancer Therapy
Vivos Inc. is a clinical‑stage radiation oncology company pioneering Precision Radionuclide Therapy (PRnT). Using a proprietary Yttrium‑90 hydrogel platform, RadioGel® for humans and IsoPet® for animals, Vivos develops therapies designed to deliver radiation directly inside solid tumors while protecting surrounding healthy tissue.
Our Values
Caring – We wish to provide a precise therapy option to humans and pets suffering from cancer.
Innovation – To deliver targeted, science-driven therapies designed to maximize impact while minimizing harm—setting new benchmarks in cancer treatment.
Teamwork – Continue to work together with the common goal in mind – to bring a new generation Precision Radionuclide Therapy™ to the world for humans and pets.
Our History
Vivos Inc. stands at the forefront of precision radiation therapy, advancing a platform designed to transform how solid tumors are treated in both humans and animals. With expanding clinical programs, a growing IsoPet® network, and a global manufacturing strategy, the company is positioned to make a meaningful impact on the future of cancer care.
RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only.
By 2026, Vivos began diversifying its manufacturing footprint with:
- A new U.S. production facility in Richland, Washington
- An international manufacturing strategy through its India subsidiary
The company continued preparing its next IDE submission for human clinical trials in the United States.
New patents and global trademark protections for PrecisionGel™ further strengthened the company’s position in targeted radionuclide therapy.
In 2025, IsoPet® experienced major commercial momentum:
-
- 1,200% year‑over‑year growth
- More than 100 animals treated
- 17 certified veterinary clinics across the United States
The company also established Vivos Scientific India LLP, expanding manufacturing, clinical operations, and future human therapy programs. New leadership roles were added to support this accelerated growth.
Between 2022 and 2024, Vivos broadened its patent portfolio, advanced new delivery and shielding technologies, and expanded manufacturing capabilities.
A defining moment came in December 2023, when the FDA granted Breakthrough Device Designation for RadioGel®, which was a significant step toward U.S. clinical trials.
By late 2024, Vivos initiated its first human treatments internationally, marking the beginning of global clinical expansion.
Vivos performed its first IsoPet® treatment in 2019, beginning a period of rapid development in hydrogel chemistry, delivery systems, and intellectual property.
During this time, the company also expanded its human therapy focus to include papillary thyroid carcinoma and related metastatic disease, strengthening its clinical pathway.
In 2017, AMIC officially became Vivos Inc., marking a strategic shift toward targeted radionuclide therapies and a renewed focus on life‑extending cancer treatments.
By 2018, the FDA Center for Veterinary Medicine (CVM) classified RadioGel® as a device for treating feline and canine cancers. Per FDA recommendations, the company adopted the IsoPe® brand to distinguish it from the human application. The first animal treatments soon followed, establishing the foundation for a growing veterinary oncology network.
Vivos Inc. originated in 1994 as Advanced Medical Isotope Corporation (AMIC), a company dedicated to advancing medical isotope technologies for diagnostic and therapeutic use. Over the next two decades, AMIC expanded into brachytherapy devices, isotope production, and radiation‑based medical tools.
A major milestone came in 2013, when the FDA determined that RadioGel® should be regulated as a medical device for human cancer therapy, opening a faster, more efficient regulatory pathway.
In 2016, the company created the IsoPet® Solutions division to adapt its technology for veterinary oncology, partnering with leading university hospitals to refine treatment protocols.
Meet Our Team
Our team includes brilliant scientists, dedicated researchers, innovative engineers, and top notch business professionals, all of whom bring unique skills and perspectives to our work.
Michael Korenko
Dr. Michael Korenko has advanced degrees from Case-Western Reserve University and MIT and was a NATO Postdoctoral Fellow at Oxford University. He served as a White House Fellow at the Department of Defense and the Office of Science and Technology. He has had several publications, 30 patents, and was awarded the Quality Manager of the year by Westinghouse Corporation, the first ever award to a manager from the US Steelworkers for excellence in promoting safety, the National Energy Resources Organization Research and Development Award, and a Friend of the Nez Pierce Nation Nez Perce Tribal Award for forming the Native American Program. He has been a successful senior manager at Westinghouse and Curtiss Wright Corporation. He has extensive experience in nuclear materials and manufacturing. As CEO he has transformed Vivos Inc from financial jeopardy into a streamlined organization focusing on Precision Radio Nuclide Therapy for animals and humans.
Carlton M. Cadwell
Dr. Carlton Cadwell leverages over 30 years of experience in the corporate world leading Cadwell Laboratories, a major international provider of neurodiagnostic devices. Dr. Carlton Cadwell brings a proven track record in business leadership and innovation.
Brad Weeks
Brad holds a Master of Business Administration with a focus on Technology Management. As President, he leads with a unique blend of experiences and expertise in the medical device and biotechnology sectors. He passionately drives business development and innovation, strategic partnerships, and team expansion to support the company’s growth in targeted radiation therapy.
Throughout his career, Brad has held key leadership roles dedicated to advancing medical technologies and improving patient outcomes. His background includes developing international collaborations — most recently helping expand the company’s global footprint through partnerships in India and other international markets.
David Swanberg
Mr. Swanberg has over 35 years’ experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project Management. He has worked in diverse organizations ranging from small start-up businesses to corporations with multi-billion-dollar annual revenues. Most recently, he served as Technology Development Project Manager for Washington River Protection Solutions, from 2010 to 2024. Prior to 2010, he served as Senior Chemical/Environmental Engineer for Science Applications International Corporation since 2008. He has also previously served as Executive Vice President of Operations for IsoRay Medical Inc. managing day-to-day operations, R&D, and New Product Development. Mr. Swanberg was a co-founder of IsoRay and led the initial Cs-131 brachytherapy seed product development, FDA 510(k) submission/clearance, and NRC Sealed Source review and registration. He led the radiation dosimetry evaluations to meet American Association of Physicists in Medicine guidelines and is a current member of the AAPM. Mr. Swanberg served on the IsoRay Board of Directors and participated in several capital financing rounds totaling over $30.0 million. Mr. Swanberg has been actively engaged with the Company in his previous role as Chief Technical Manager since 2017. He has been integrally involved in product development, production, user training, regulatory submissions, and intellectual property development. He holds a BA in Chemistry from Bethel University (MN) and an MS in Chemical Engineering from Montana State University. He has numerous technical publications and holds several patents.
Dr. Jim Duncan
Dr. Duncan is a Doctor of Philosophy, holds a Master of Science in Immunochemistry, a Bachelor of Science in Bacteriology and Chemistry. With more than 30 years experience and countless projects, publications and patents under his belt he has worked for the Department of Defense bringing concepts from the laboratory to production. Dr. Duncan oversees the production of more Peltier Chillers.
Frederick Swindler
Mr. Swindler has a B.S. Biomedical Engineering, a M.B.A and is an ISO 9000 Auditor. With over 50 years in the industry Mr. Swindler offers Vivos extensive expertise in quality assurance and regulatory affairs in the medical device industry with specific emphasis in development and auditing of quality systems and product submissions.
LeeAnna Binder
LeeAnna supports client relations and clinic engagement for the company, bringing more than 30 years of experience in sales, customer service, and business development. Her background spans multiple industries where she was involved in building companies from the ground up, giving her a strong foundation in operations, communication, and customer support. Her passion lies with establishing long-term connections in the veterinary oncology community.
Along with a Business Management Diploma, LeeAnna is also currently completing her PhD in Integrative Medicine with an emphasis on cancer. LeeAnna is also the pet parent of her dachshund Finnegan, who is her loyal travel companion on clinic visits across the United States.
Megan Binder
Megan supports both human and veterinary divisions in the company, streamlining internal systems and supporting company growth initiatives. She holds a Bachelor of Arts from the University of British Columbia and a Master of Arts degree in Clinical Psychology, which has provided her with a thoughtful, human-centered lens that serves as a strong foundation when communicating across teams, clinics, and partners.
Working largely behind the scenes, Megan is dedicated to supporting daily operations with steady efficiency — helping maintain alignment across departments, and contributing to the polished communication standards across technical, quality, and marketing divisions that represent the company’s brand.
Halle Binder
Halle supports the company’s internal processes, maintaining, organizing, and overseeing accurate documentation across departments. She is currently completing her undergraduate degree at MacEwan University and has a talent for bringing order to busy workflows, helping the team operate smoothly and efficiently.
As the comforting voice responding to pet inquiries, Halle’s work assists clinics across the United States. She brings reliability, structure, and a solutions-oriented attitude to every task.
Sandip Bali
With over two decades of expertise in the fields of radiotherapy, radioembolization, and interventional oncology, Mr. Bali has an extensive track record of driving business development across the Middle East, Africa, and Asia. His professional journey includes leadership roles at esteemed organizations such as Nordion Inc., Sirtex Medical, Novoste Corporation, and Telix Pharmaceuticals India.